ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism.
作者信息
Porres-Aguilar Mateo
机构信息
Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, Department of Internal Medicine, Divisions of Hospital and Adult Thrombosis Medicine, El Paso, Texas, United States of America.
出版信息
J Vasc Bras. 2023 Jun 19;22:e20230051. doi: 10.1590/1677-5449.202300512. eCollection 2023.
Abstract
摘要
相似文献
1
ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism.使用XI因子/XIa因子抑制剂进行静脉血栓栓塞的血栓预防
J Vasc Bras. 2023 Jun 19;22:e20230051. doi: 10.1590/1677-5449.202300512. eCollection 2023.
2
A Review of FXIa Inhibition as a Novel Target for Anticoagulation.凝血因子Ⅺa抑制作为抗凝新靶点的综述
Hamostaseologie. 2023 Feb;43(1):28-36. doi: 10.1055/a-1984-7021. Epub 2023 Feb 20.
3
Venous Thromboembolism After Knee Arthroscopy in Undiagnosed Familial Thrombophilia.未诊断出的家族性易栓症患者膝关节镜检查后的静脉血栓栓塞症
Orthopedics. 2016 Nov 1;39(6):e1052-e1057. doi: 10.3928/01477447-20160719-02. Epub 2016 Jul 27.
4
Role of charged groups in factor XI/XIa activity.带电基团在因子XI/ XIa活性中的作用。
J Biol Chem. 1982 Oct 10;257(19):11284-7.
5
Identification of a factor IX binding site on the third apple domain of activated factor XI.活化因子XI第三个苹果结构域上因子IX结合位点的鉴定。
J Biol Chem. 1996 Nov 15;271(46):29023-8. doi: 10.1074/jbc.271.46.29023.
6
The role of clinically significant venous thromboembolism and thromboprophylaxis in pediatric patients with pelvic or femoral fractures.临床显著静脉血栓栓塞及血栓预防在骨盆或股骨骨折儿科患者中的作用
J Pediatr Orthop. 2012 Jun;32(4):357-61. doi: 10.1097/BPO.0b013e31824b2a07.
7
Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.作为新型抗凝靶点的凝血因子XIa抑制剂：近期临床研究进展
Pharmaceuticals (Basel). 2023 Jun 11;16(6):866. doi: 10.3390/ph16060866.
8
A new sensitive assay for bovine activated factor XI (factor XIa) using a reconstituted coagulation cascade system.一种使用重组凝血级联系统检测牛活化因子XI（因子XIa）的新型灵敏检测方法。
Thromb Res. 1987 Nov 15;48(4):461-74. doi: 10.1016/0049-3848(87)90403-8.
9
Factor XIa-alpha 1 antitrypsin complex--elevation in the patients with DIC.凝血因子XIa-α1抗胰蛋白酶复合物——在弥散性血管内凝血患者中升高。
Thromb Res. 1986 Nov 15;44(4):489-501. doi: 10.1016/0049-3848(86)90327-0.
10
Factor XI as a Therapeutic Target.凝血因子XI作为治疗靶点。
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1316-22. doi: 10.1161/ATVBAHA.116.306925. Epub 2016 May 12.
引用本文的文献
1
Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study.口服FXA抑制剂相关的严重急性脑出血用andexanet alfa：来自ANNEXA-I研究对临床相关血栓栓塞事件的见解。
J Vasc Bras. 2025 Jan 20;23:e20240133. doi: 10.1590/1677-5449.202401332. eCollection 2024.
2
Anticoagulation in the Management of Acute Pulmonary Embolism-A Review.急性肺栓塞治疗中的抗凝——综述
Int J Angiol. 2024 Mar 12;33(2):95-100. doi: 10.1055/s-0044-1782537. eCollection 2024 Jun.
本文引用的文献
1
Pharmacology and Clinical Development of Factor XI Inhibitors.因子 XI 抑制剂的药理学和临床开发。
Circulation. 2023 Mar 14;147(11):897-913. doi: 10.1161/CIRCULATIONAHA.122.062353. Epub 2023 Mar 13.
2
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.因子 XIa 抑制剂药物的临床评估：JACC 本周综述主题。
J Am Coll Cardiol. 2023 Feb 28;81(8):771-779. doi: 10.1016/j.jacc.2022.11.057.
3
Factor XI Inhibitors for the Prevention of Thrombosis: Towards Safer Anticoagulation Strategies.用于预防血栓形成的因子XI抑制剂：迈向更安全的抗凝策略
Arch Med Res. 2023 Feb;54(2):160-161. doi: 10.1016/j.arcmed.2022.11.018. Epub 2022 Dec 13.
4
Factor XI as a target for preventing venous thromboembolism.将因子XI作为预防静脉血栓栓塞的靶点。
J Thromb Haemost. 2022 Mar;20(3):550-555. doi: 10.1111/jth.15628. Epub 2022 Jan 12.
5
Milvexian for the Prevention of Venous Thromboembolism.密尔沃基用于预防静脉血栓栓塞。
N Engl J Med. 2021 Dec 2;385(23):2161-2172. doi: 10.1056/NEJMoa2113194. Epub 2021 Nov 15.
6
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week.因子 XI 抑制：将血栓形成与止血分离——JACC 本周综述专题。
J Am Coll Cardiol. 2021 Aug 10;78(6):625-631. doi: 10.1016/j.jacc.2021.06.010.
7
Abelacimab for Prevention of Venous Thromboembolism.Abelacimab 用于预防静脉血栓栓塞。
N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19.
8
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.奥索司他单抗预防膝关节置换术患者静脉血栓栓塞的效果：FOXTROT 随机临床试验。
JAMA. 2020 Jan 14;323(2):130-139. doi: 10.1001/jama.2019.20687.
9
Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events.因子 XI 缺乏与心血管和静脉血栓栓塞事件的风险降低相关。
Blood. 2017 Mar 2;129(9):1210-1215. doi: 10.1182/blood-2016-09-742262. Epub 2016 Dec 30.
10
Factor XI antisense oligonucleotide for prevention of venous thrombosis.XI 因子反义寡核苷酸预防静脉血栓形成。
N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.
Zotero 插件